
9M 2024 Financial Results



## Business Highlights

Manuela Franchi Group CEO



## 9M Business Highlights

- €8bn total GBV from new business in 9M 2024 already reaching the €8bn annual target. Expected to exceed target by YE24
- EBITDA ex NRI at €96m, above management expectations
- Confirmed FY 2024 guidance
- Gardant transaction and right issue on track to close by Q4 2024
- Execution of final financing package at €526m (above initial indications)

New Business¹ €8bn

EBITDA ex NRIs €96m

Guidance confirmed

Gardant closing expected in **2024** 

Refinancing package obtained €526m

Powering market leadership and accelerating growth through new business and the Gardant acquisition



## Prudently set assumptions on new business validated by market trends

### **Assumptions at Capital Markets Day**

#### **Current State**

Market

Italian market



~**€70-75bn NPE transactions** in 2024-2026

**Stable forecast** as of Sep-2024<sup>(1)</sup>



Pipeline (2)



**€40bn pipeline** next 18 months

**€33bn pipeline + €6bn new business**closed since CMD



**GBV** 



**-2% CAGR in GBV** 2023A-2026E

**+2% growth in GBV** in 9M 2024<sup>(3)</sup>



oValu

New mandates



~**€6bn p.a. new mandates** in 2024-2026

~€6bn new mandates in 9M 2024



Forward Flows



~**€2bn p.a. forward flows** in 2024-2026

>€2bn forward flows in 9M 2024 (to increase post-Gardant)







- (1) Banca Ifis NPL Market watch report September 2024
- (2) Pipeline includes forward flows
- (3) Including secondary deals on existing portfolios

## Strong new business intake YTD

#### **GBV FROM NEW BUSINESS IN 2024 YTD**





New mandates at €5.7bn YTD in line with annual target set for 2024-2026


Forward Flows above annual target set for 2024-26 in 9m24, to be further supported by Gardant's LT agreements with Banco BPM and BPER in 2025-26

>90% market share on closed deals in Greece and 100% of servicing mandates retained following secondary market on managed portfolios

>21% Market share on closed deals in Spain



## Visible Pipeline Providing Room for Future GBV Growth



Strong pipeline with most adjustments coming from won mandates or projects postponed by banks



## Diversification program continues according to plan

**ENGINE 2 OF GROWTH** 

doAdvise fully operational, sole advisor on 90% of doValue sales in Greece since inception, and co-advisor on the remaining 10%



Cross selling with insurance companies to expand product offering in Spain



FinThesis received regulatory approval in
October
Aiming to be live in early 2025



doValue Res received license to participate to digital public auction

**UTP AND STAGE 2** 

New mandates for €600m GBV of UTPs and Stage2 added to Efesto in Italy in Q3

€0.5bn increase to the equity commitment of Efesto fund

by banks, fueling future UTP contributions

**Expansion of Stage 2** management and asset management lines of business ongoing, to be accelerated by Gardant acquisition

doValue

## Update on Transformation capex plan

Enabling of new businesses driving collections as well as our Engine 2 of growth

50% of 2024 investments strategically deployed across three

main areas



Stage 2 model

**Real Estate** 

**Granular tickets** 

**Al-powered collection** models





Driving operational efficiency through AI-driven segmentation, debtor digitalisation, vertical integration of systems, legal services automation



Ensuring resilience and long-term sustainability of operations through security programs, data strategy and data quality programs, AI driven text mining



## EMARKET SDIR CERTIFIED

## Gardant acquisition moves us closer to our 2026 Business Plan objectives

Closing



Closing of acquisition and subsequent rights issue expected within Q4

Guidance



Confirmed Guidance for Gardant of €50m EBITDA for 2024

**Synergies** 



Confirmed €15 million synergies by 2026 (20% revenue, 80% cost)

Integration



Completed integration plan to be deployed as soon as the deal closes

**Cash Position** 



**Strong cash generation** as envisaged, to have positive impact at closing. Through **locked-box mechanism** doValue retains cash generated by Gardant since Dec 2023

Financing



Upsized bank financing package at €526m (€446m 5-years term loan and €80m RCF), provide for repayment of the 2025 notes, and back-up for the 2026 notes

doValue

## Financial Results

Davide Soffietti Group CFO




## Financials at a glance

ITEMS (*)	Q3 2024	Q3 2023	Δ% YoY	9M 2024	9M 2023	Δ% YoY	COMMENTS
Gross Revenues	€100m	€105m	(4.8)%	€314m	€332m	(5.4)%	<ul> <li>Gross revenues trend driven by lower REOs in Spain and delayed disposals in Greece</li> <li>In Q3 higher servicing revenues offset by negative ancillaries in Greece</li> </ul>
Net Revenues	€91m	€96m	(5.3)%	€283m	€302m	(6.4)%	Higher ancillaries in Italy driving growing outsourcing costs
EBITDA ex NRIs	€28m	€36m	(20.1)%	€96m	€117m	(18.3)%	<ul> <li>EBITDA exceeded management expectations for the 9 months</li> <li>Improved cost containment in Spain mitigated the trend in direct margin</li> </ul>
EBITDA ex NRIs margin	28.4%	33.8%	(5.5) p.p.	30.5%	35.3%	(4.8) p.p	<ul> <li>EBITDA margin slightly decreased in Q3 vs H1 due to seasonality</li> <li>Trend vs. prior year driven by lower disposals in 3Q</li> </ul>
Net Income ex NRIs	€(2)m	€(28)m	(92.4)%	€5m	€(10)m	<100%	<ul> <li>Net income change mostly attributable to the 9M 2023 base affected by the impairment of assets in Iberia</li> <li>Slight loss in Q3 driven by lower EBITDA</li> </ul>
Net Income	€(5)m	€(30)m	(82.8)%	€10m	€(26)m	<100%	• Improved net income primarily thanks to positive effect on taxes due to Tax Claim in Spain (+€20.1m) in 1H24



### **Gross Revenues**



#### **COMMENTS**

#### Group

 Gross revenues slightly decreasing YoY driven by lower disposals, partially offset by higher ancillaries in Italy in 9M24, further increasing diversification of revenue

#### Hellenic Region

- Revenues down (6.4)% YoY, due lo lower disposals in Greece, expected to pick up in
- Lower NPL and UTP revenues partly offset by sequential improvement in Q3

#### Italy


- Overall revenues up +2.0% YoY
- Strong growth in ancillaries were offset by flat NPLs and lower UTPs

#### Spain

• Revenues down (19.4)% YoY due to declining REOs



## **Operating Expenses**



#### **COMMENTS**

#### **Total Operating expenses**

• Successfully decreased operating costs YoY in 9M 2024, despite the tough comparison base due to one-off events thanks to continued cost discipline

#### • HR


 Stable HR cost (+0.5% YoY) as the combined effect of one-off positive element in 2023 and 15% wage inflation in Italy in 2024 coupled with delay of planned exits after Gardant closing which were more than offset by cost discipline across geographies

#### IT, RE and SG&A

 Effective cost discipline practices implemented at group level re-balanced the natural increases in IT, real estate and other general & administration costs of +3.2% YoY



### EBITDA ex NRIs



#### **COMMENTS** (1)

#### Group

- Results above management expectations
- EBITDA at €96.5m in 9M 2024 (-18.3% YoY)
- Decline mainly driven by corresponding lower direct revenues and unfavorable comparison base linked to the release of provisions for former CEO MBO (€5.9m)

#### **Hellenic Region**

 Hellenic EBITDA impacted by lower Net Revenues (€(11.5)m YoY), with marginality improving in Q3 on track to return to around 50%, in line with the past

#### • Italy (2)

- EBITDA decrease driven by the combination of 15% wage inflation, the delay of planned exits, as well as the one-off effect from the former CEO's MBO
- Exits delayed pending strategic assessment following the Gardant acquisition

#### Spain


 EBITDA back in positive territory and sequential improvement in margin in 3Q24 reflect continued efforts in achieving a highly flexible cost structure



- (1) EBITDA refers to recurring EBITDA excluding NRIs(2) EBITDA for Italy including Group costs unchanged versus prior year

#### EMARKET SDIR CERTIFIED

## From EBITDA to Attributable Net Income



- · Lower write-downs on PP&E and intangibles in line with collection curves, supported also by the favorable comparison base
- Slightly higher net provisions due to the reversal of the previous year's provision related to Sareb, partly offset by lower layoffs than expected in Italy. (€3)m linked to the valuation at disposal of doValue Portugal in July following sale
- Financial interest and commission broadly stable despite increasing interest rates thanks to fixed rates structure and the positive effect from the tax rate component on interest
- Income tax for the period positively impacted by the non-recurring outcome related to the Spanish Tax Claim



## **Cash Flow**


€m	Q3 2023	Q3 2024	9M 2023	9M 2024
EBITDA	35.5	27.1	115.3	92.2
Capex	(3.7)	(5.7)	(9.2)	(12.3)
Change in NWC	(16.5)	(8.3)	(10.3)	(18.5)
Change in other assets & liabilities	(0.7)	(9.1)	(57.9)	(37.6)
Cash Flow from Operations	14.6	4.0	38.0	23.7
Taxes	(5.8)	(5.8)	(20.0)	(14.8)
Financial charges	(11.6)	(12.0)	(23.3)	(24.3)
Financial assets divestments/(investments)	1.6	1.4	2.4	2.8
Free Cash Flow to Equity	(1.3)	(12.3)	(3.0)	(12.6)
Dividends paid	(5.2)	-	(52.6)	-
Equity divestments/(investments)	-	(2.8)	-	(6.2)
Net cash Flow	(6.4)	(15.1)	(55.6)	(18.9)

#### **COMMENTS**

- Cash flow from operations, equal to €23.7m, in 9M, €(14.3)m lower than LY (€38.0m) driven by €(23.2)m lower EBITDA and:
  - Increase in Capex (+€3.2m YoY), in line with the transformation plan and the transition year previously announced
  - NWC absorption linked to prepayment of expenses which will be reversed in Q4, and to portfolio sales booked in P&L following signing of binding agreement that are pending onboarding and hence cash payment, partially reversed in Q4
- Towards the normalization of change in other asset and liabilities, absorption is mainly composed by:
  - Payments of lease liability: €(12.7)m
  - Payments for redundancies: €(10)m
  - Payments for legal cases, personnel, and payments of prior year provisions:
     €(5.3)m
- (Investments)/divestments in financial assets, equal to +€2.8m, mainly referred to cash distributions from co-investment assets
- Equity Investment equal to €(6.2)m includes:
  - the acquisition of Team4 in Spain in 2023 €(0.4)m
  - disposal of doValue Portugal and other €(3.2)m
  - Share buy-back equal to €(3.4)m as last part of the program launched in Q4 2023




### **Financial Structure**



#### **COMMENTS**

- Decrease in cash position in Q3 mostly due to lower EBITDA
- **Net leverage in line with seasonality** at 3.1x due to combined effect of cash absorption in Greece and lower LTM EBITDA
- Significant cash-in in April related to arbitration with Altamira Asset Management Holding (€22.7m) and success on Greek disposals recorded as revenue in Q4 2023
- Liquidity buffer of €173.0 m including undrawn RCF lines
- Stable corporate rating (BB/Stable Outlook) despite wave of downgrades among peer group
- Upsized €526mn bank financing package for the Gardant transaction including 5year amortising term loan and €80mn 3-year revolving facilities, provides for the repayment of the 2025 notes, and back-up for the repayment of the 2026 notes


#### **Seasonality in Leverage Across Quarters**





#### EMARKET SDIR CERTIFIED

## Regional Performance





## Guidance Confirmed

Davide Soffietti Group CFO

## EMARKE SDIR CERTIFIED

## Guidance confirmed for 2024 and 2026

	2024 DOVALUE <sup>1</sup>	2024 GARDANT	2026 NEW DOVALUE	COMMENTS
Gross revenues	€460-480m	€135m	€605-625m	<ul> <li>Non-NPL revenues to ~ 40-45% from 30-35% in 2024</li> </ul>
Gross Book Value	~€115bn	~€22bn	~€130bn	<ul> <li>Annual Collection Rate to increase to 5.5% by 2026 thanks to younger and higher quality masses</li> <li>~€8bn p.a. new business (€6bn new mandates, €2bn future flows)</li> </ul>
EBITDA ex NRIs	€155-165m	€50m	€240-255m	<ul> <li>EBITDA margin to reach c. 40% by 2026</li> <li>Includes €15 million synergies</li> </ul>
FCF <sup>(2)</sup>	n.a.	n.a.	€90-95m	<ul> <li>Free cash flow after interest expenses of €35-40m to serve dividence and principal repayment. Includes the following assumptions:         <ul> <li>lower tax rate thanks to DTA becoming effective in 2025</li> <li>€30m redundancies in 2024 and €5-10m thereafter</li> <li>€12m earn-out in 2026 for 2nd instalment of doValue Greece</li> </ul> </li> </ul>
Financial leverage	2.8x - 3.0x		1.3x - 1.5x <sup>(3)</sup>	Positive cash generation will support deleverage by 2026





# Appendix

## Acquisition process status

Q3 2024 Q4 2024



Illustrative assuming regulatory timely authorizations


- Regulatory approval process ongoing and includes, among others, Bank of Italy, Consob, other National Central Banks
- EGM resolved on: reverse stock split; new by-laws, increased number of BoD members, reserved capital increase for purchase of Gardant, rights issue
- Reverse stock-split: 1 new share each 5 shares (new ISIN) executed. Number of total ordinary shares outstanding decreased from 80m to 16m
- Reserved capital increase for convertible bonds: before closing, the sellers of Gardant will receive through a cashless transaction zero-coupon convertibles notes which will automatically convert, immediately after the commencement of the rights issue period, into 4m newly issued doValue shares corresponding to 20% of the company's share capital (Equity Consideration). The converted shares are subject to a lock-up period between 6 and 12 months (Elliott 12 months)
- Rights issue: subject to closing of the Gardant Acquisition, €150m rights issue to be backed by anchor shareholders (Fortress, Bain, Elliott) and certain Gardant's minority shareholders for ca. €82.5m and by a pre-underwriting agreement with banks for ca. €67.5m (subject to customary conditions)

#### **COMMENTS**

- EGM took place on the September 11<sup>th</sup>, 2024
- Acquisition closing date expected within Q4 2024
- Rights issue to launch after closing, dependant on M&A closing and regulatory approvals
- Regulatory approval process ongoing
- Effective date 31/12/2023: benefit of Gardant cash flow to doValue for full 2024



## **GBV** dynamics



#### **COMMENTS**

**Resilient GBV dynamic:** natural GBV reduction being offset by stable inflows from existing clients and solid new business

- Inflows from new clients: stable vs LY (+0.8%). Intakes by region worth €0.3bn from Italy, more than 80% NPLs, €4.8bn from the Hellenic Region, mainly NPLS, of which €2.5bn secondary mandates, €1.1bn from Spain, almost all mixed NPL/REO mandates from Sabadell, BBVA and investors.
- Committed mandates among which €0.3bn announced in July and €0.3bn in September, from Efesto fund in Italy and €1.3bn in the Hellenic Region, the first of three tranches of a portfolio sale





## **Condensed Income Statement**

(6,1000)	0.400.4000.4	9/30/2023	Obara va C	Ob an an Or
(€/000)	9/30/2024	Restated	Change €	Change %
Servicing Revenues:	272,793	291,498	(18,705)	(6.4)%
o/w: NPE revenues	240,614	251,623	(11,009)	(4.4)%
o/w: REO revenues	32,179	39,875	(7,696)	(19.3)%
Co-investment revenues	1,025	1,064	(39)	(3.7)%
Ancillary and other revenues	42,886	42,592	294	0.7%
Gross revenues	316,704	335,154	(18,450)	(5.5)%
NPE Outsourcing fees	(8,421)	(10,692)	2,271	(21.2)%
REO Outsourcing fees	(6,648)	(7,256)	608	(8.4)%
Ancillary Outsourcing fees	(16,850)	(12,569)	(4,281)	34.1%
Net revenues	284,785	304,637	(19,852)	(6.5)%
Staff expenses	(140,777)	(141,751)	974	(0.7)%
Administrative expenses	(51,856)	(47,551)	(4,305)	9.1%
0.W. IT	(20,415)	(19,604)	(811)	4.1%
o.w. Real Estate	(3,707)	(3,801)	94	(2.5)%
o.w. SG&A	(27,734)	(24,146)	(3,588)	14.9%
Operating expenses	(192,633)	(189,302)	(3,331)	1.8%
EBITDA	92,152	115,335	(23,183)	(20.1)%
EBITDA margin	29.1%	34.4%	(5.3)%	(15.4)%
Non-recurring items included in EBITDA	(3,635)	(79)	(3,556)	
EBITDA excluding non-recurring items	95,787	115,414	(19,627)	n.s. (17.0)%
EBITDA excluding non-recurring items	30.5%	34.4%		
	30.3%	34.4%	(3.9)%	(11.4)%
Net write-downs on property, plant, equipment and	(42,834)	(76,437)	33,603	(44.0)%
intangibles Not provisions for risks and sharpes	(12.060)	(12.015)	(0.5.4)	6.60/
Net provisions for risks and charges	(13,869)	(13,015)	(854)	6.6%
Net write-downs of loans	121	1,207	(1,086)	(90.0)%
Profit (loss) from equity investments	(2,959)	-	(2,959)	N.S.
EBIT  Not income (loca) on financial coacts and liabilities	32,611	27,090	5,521	20.4%
Net income (loss) on financial assets and liabilities	(1,405)	1,586	(2,991)	n.s.
measured at fair value				(01.0)0
Net financial interest and commissions	(18,619)	(23,614)	4,995	(21.2)%
EBT	12,587	5,062	7,525	148.7%
Non-recurring items included in EBT	(14,850)	(11,833)	(3,017)	25.5%
EBT excluding non-recurring items	27,437	16,895	10,542	62.4%
Income tax for the period	3,848	(30,996)	34,844	(112.4)%
Profit (Loss) for the period	16,435	(25,934)	42,369	n.s.
Profit (loss) for the period attributable to Non-controlling	(6,094)	267	(6,361)	n.s.
interests		<del>-</del>	(0,00.)	
Profit (Loss) for the period attributable to the Shareholders of the Parent Company	10,341	(25,667)	36,008	(140.3)%
Non-recurring items included in Profit (loss) for the period	5,369	(12,249)	17,618	(143.8)%
O.w. Non-recurring items included in Profit (loss) for the				
period attributable to Non-controlling interest	(153)	(784)	631	(80.5)%
Profit (loss) for the period attributable to the Shareholders				
	4,819	(14,202)	19,021	(133.9)%
of the Parent Company excluding non-recurring items				•
Profit (loss) for the period attributable to Non-controlling	6,247	517	5,730	n.s.
interests excluding non-recurring items				
Earnings per share (in Euro)	0.67	(1.62)	2.29	(141.2)%
Earnings per share excluding non-recurring items (Euro)	0.31	(0.90)	1.21	(134.7)%



#### EMARKET SDIR CERTIFIED

## **Condensed Balance Sheet**

(€/000)	9/30/2024	12/31/2023	Change €	Change %
Cash and liquid securities	90,509	112,376	(21,867)	(19.5)%
Financial assets	41,945	46,167	(4,222)	(9.1)%
Property, plant and equipment	41,936	48,678	(6,742)	(13.9)%
Intangible assets	454,701	473,784	(19,083)	(4.0)%
Tax assets	87,027	99,483	(12,456)	(12.5)%
Trade receivables	174,544	199,844	(25,300)	(12.7)%
Assets held for sale	10	16	(6)	(37.5)%
Other assets	70,414	51,216	19,198	37.5%
Total Assets	961,086	1,031,564	(70,478)	(6.8)%
Financial liabilities: due to banks/bondholders	585,018	588,030	(3,012)	(0.5)%
Other financial liabilities	68,767	96,540	(27,773)	(28.8)%
Trade payables	63,209	85,383	(22,174)	(26.0)%
Tax liabilities	56,771	65,096	(8,325)	(12.8)%
Employee termination benefits	8,147	8,412	(265)	(3.2)%
Provisions for risks and charges	26,451	26,356	95	0.4%
Other liabilities	37,597	57,056	(19,459)	(34.1)%
Total Liabilities	845,960	926,873	(80,913)	(8.7)%
Share capital	41,280	41,280	<del>-</del>	n.s.
Reserves	15,097	35,676	(20,579)	(57.7)%
Treasury shares	(9,347)	(6,095)	(3,252)	53.4%
Profit (loss) for the period attributable to the Shareholders of the Parent Company	10,341	(17,830)	28,171	n.s.
Net Equity attributable to the Shareholders of the Parent Company	57,371	53,031	4,340	8.2%
Total Liabilities and Net Equity attributable to the Shareholders of the Parent Company	903,331	979,904	(76,573)	(7.8)%
Net Equity attributable to Non-Controlling Interests	57,755	51,660	6,095	11.8%
Total Liabilities and Net Equity	961,086	1,031,564	(70,478)	(6.8)%



#### EMARKET SDIR CERTIFIED

## **Condensed Cash Flow**

(€/000)	9/30/2024	9/30/2023	12/31/2023
EBITDA	92,152	115,335	175,345
Capex	(12,332)	(9,160)	(21,361)
EBITDA-Capex	79,820	106,175	153,984
as % of EBITDA	87%	92%	88%
Adjustment for accrual on share-based incentive system payments	(176)	(4,761)	(5,853)
Changes in Net Working Capital (NWC)	(18,536)	(10,269)	(10,673)
Changes in other assets/liabilities	(37,450)	(53,175)	(58,301)
Operating Cash Flow	23,658	37,970	79,157
Corporate Income Tax paid	(14,820)	(19,961)	(27,595)
Financial charges	(24,310)	(23,329)	(23,329)
Free Cash Flow	(15,472)	(5,320)	28,233
(Investments)/divestments in financial assets	2,832	2,285	2,599
Equity (investments)/divestments	(3,194)	<del>-</del>	(21,520)
Tax claim payment	400	<del>-</del>	_
Treasury shares buy-back	(3,421)	<del>-</del>	(2,115)
Dividends paid to minority shareholders	<del>-</del>	(5,000)	(5,000)
Dividends paid to Group shareholders	<del>-</del>	(47,618)	(47,992)
Net Cash Flow of the period	(18,855)	(55,653)	(45,795)
Net financial Position - Beginning of period	(475,654)	(429,859)	(429,859)
Net financial Position - End of period	(494,509)	(485,512)	(475,654)
Change in Net Financial Position	(18,855)	(55,653)	(45,795)



## Glossary

ВРО	Business Process Outsourcing, i.e. the outsourcing of non-strategic support activities by banks
Early Arrears	Loans that are up to 90 days past due
Forward Flows	Agreement with commercial bank related to the management of all future NPL generation by the bank for number of years, customary feature of credit servicing platforms spun off by commercial banks
FTE	Full Time Equivalent, i.e. a unit that indicates the workload of an employed person in a way that makes workloads comparable across various contexts
GACS	Garanzia Cartolarizzazione Sofferenze, i.e. the State Guarantee scheme put together by the Italian Government in 2016 which favoured the creation of a more liquid NPL market in Italy and allowed banks to more easily deconsolidate NPL portfolios through securitisations
GBV	Gross Book Value, i.e. nominal value of assets under management by doValue, represents the maximum / nominal claim by banks / investors to borrowers on their portfolios
HAPS	Hercules Asset Protection Scheme, i.e. the State Guarantee scheme put together by the Greek Government in 2019 with the aim of favouring the creation of a more liquid NPL market in Greece and to allow banks to more easily deconsolidate NPL portfolios through securitisations
NPE	Non-Performing Exposure, i.e. the aggregate od NPL, UTP and Early Arrears
NPL	Non-Performing Loan, i.e. loans which are more than 180 days past due and have been denounced
NRI	Non-Recurring Items, i.e. costs or revenues which are non-recurring by nature (typically encountered in M&A or refinancing transactions)
Performing Loans	Loans which do not present problematic features in terms of principal / interest repayment by borrowers
REO	Real Estate Owned, i.e. real estate assets owned by a bank / investor as part of a repossession act
Stage 2 Loans	Subperforming loans – albeit not NP - that have seen a significant increase in credit risk, resulting in "investment grade" credit quality
UTP	Unlikely to Pay, i.e. loans that are between 90-180 days past due and denounced or more than 180 past due and not denounced

doValue



## Disclaimer

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.

This presentation is not a prospectus and not an offer of securities for sale to U.S. persons or in any jurisdiction, including in or into the United States, Canada, Japan or Australia.

This disclaimer applies to all documents and information provided herein and to any verbal or written comments of person presenting them by doValue S.pA. and its affiliates ("doValue"). or any person on behalf of doValue, and any question and answer session that follows the oral presentation (collectively, the "Information"). in accessing the Information, you agree to be bound by the following terms and conditions. The Information may not be reproduces redistributed, published or passed on to any other person, directly or indirectly, in whole or In part, for any purpose.

This presentation and any materials distributed in connection herewith, taken together with any such verbal or written comments, including the contents thereof and the Information (together, the "Presentation") is not intended for potential investors and do not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe any securities, and neither this Presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, or act as an inducement to enter into, any contract or commitment whatsoever. Any such offer would only be made by means of formal offering documents, the terms of which shall govern in all respects.

You are cautioned against using this information as the basis for making a decision to purchase any security or to otherwise engage in an investment advisory relationship with doValue S.p.A. and its affiliates. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions may constitute a violation of the laws of any such other jurisdiction.

This Presentation has been prepared based on the information currently available to us and is based on certain key underlying assumptions. The information has not been independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, reasonableness or correctness of the information or opinions contained herein. None of doValue its subsidiaries or any of their respective employees, advisers, representatives or affiliates shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this Presentation. The information contained in this Presentation is provided as at the date of this Presentation and is subject to change without notice.

Statements made in this Presentation may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements, including specifically any guidance or projection, are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them.

Forward-looking statements contained in this Presentation and, in particular, in any relevant guidance, regarding trends or current activities are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict because they relate to events and depend on circumstances that may may/will occur in the future therefore should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements and guidance contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Estimated and assumptions are inherently uncertain and are subject to risks that are outside of the company's control. Any guidance and statement refers to events and depend upon circumstances that may or may not verify in the future and refer only as of the date hereof. Therefore the Company's actual results may differ materially and adversely from those expressed or implied in any forward-looking statements.

Neither doValue S.p.A. nor any of its affiliates is under any obligation, future events or otherwise.

You should not place undue reliance on any such forward-looking statements and or guidance, which speak only as of the date of this Presentation. The inclusion of the projections herein should not be regarded as an indication that the doValue considers the latter to be a reliable prediction of future events and the projections should not be relied upon as such. Use of different methods for preparing, calculating or presenting information may lead to different results and such differences may be material. It should be noted that past performance is not a guide to future performance. Please also note that interim results are not necessarily indicative of full-year results.

By reviewing the Presentation, you acknowledge that you are knowledgeable and experienced with respect to its financial and business aspects and that you will conduct your own independent investigations with respect to the accuracy, completeness and suitability of the matters referred to in the Presentation should you choose to use or rely on it, at your own risk, for any purpose.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein.

The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Davide Soffietti, in his position as manager responsible for the preparation of financial reports, certifies pursuant to paragraph 2, article 154-bis of the Legislative Decree n. 58/1998, that data and accounting information disclosures herewith set forth correspond to the company's evidence and accounting books and entries.

**Investor Relations Contacts** 

Daniele Della Seta Head of Group M&A, Strategic Finance and Investor Relations investorrelations@dovalue.it



